Why AdaptImmune collected $27.5M from GSK
Adaptimmune received a $27.5 million payment from GlaxoSmithKline following the transitioning of a T-cell therapy program targeted solid tumors from one company to the other.
As a result of the transition, GSK has assumed full responsibility for the future research, development, and potential commercialization of Adaptimmune's NY-ESO SPEAR T-cell therapy being looked as a potential treatment for a variety of cancers including non-small cell lung cancer, metastatic mela noma, ovarian and multiple…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries